FDA chief to depart after Trump signed off on ousting him

FDA chief to depart after Trump signed off on ousting him

FDA chief to depart after Trump – Food and Drug Administration Commissioner Marty Makary has announced his exit from the Trump administration, according to multiple sources close to the situation. The decision followed President Donald Trump’s approval of a plan to remove Makary last week, marking a significant shift in leadership at the agency. Makary, who had been in the role since March 2025, faced mounting challenges both internally and externally, culminating in his departure despite earlier efforts to retain his position.

Pressure from Within and Outside the Administration

Makary’s tenure was characterized by persistent scrutiny from within the White House and the Health and Human Services Department. His stance on flavored e-cigarettes, which he opposed due to concerns about youth vaping, became a focal point of this tension. Trump directly confronted him about the issue, prompting internal debates over policy direction. This disagreement was not isolated; it extended to external groups, including pharmaceutical companies and anti-abortion advocates, who questioned his decisions and leadership approach.

“The search for a new Commissioner is already underway, and we will move forward with urgency.”

Health and Human Services Secretary Robert F. Kennedy Jr. highlighted the ongoing process of finding a replacement in a recent post, emphasizing the administration’s resolve. However, the transition comes amid a backdrop of administrative instability, as the FDA has seen frequent leadership changes. Trump’s decision to replace Makary signals a broader effort to align the agency with his priorities, particularly in the health sector.

Appointment of Acting Chief and New Vacancy

Deputy Commissioner Kyle Diamantas, who leads the agency’s food division, is set to assume the role of acting FDA chief. This move was confirmed by two individuals aware of the decision, with Trump later endorsing the change on his social media platform. While Diamantas will step in temporarily, the administration now faces the task of securing a permanent successor, a process requiring Senate approval.

The departure of Makary adds to the list of high-profile vacancies in the health department. Currently, there is no confirmed leader for the Centers for Disease Control and Prevention, and the position of surgeon general remains unfilled. These gaps have raised concerns about the consistency of policy implementation and the agency’s ability to respond effectively to public health issues.

Political Considerations and Internal Dynamics

Despite the administration’s dissatisfaction with Makary’s leadership, some Trump advisors hesitated to act. They worried that removing another top official might alienate the “Make America Healthy Again” movement, which has been a key political base. However, the urgency of the situation and the need to streamline decision-making led to his ouster. The White House and HHS officials who supported the move believe it is essential to reestablish control and strengthen ties with industry stakeholders before the November elections.

Senior staff restructuring is also being considered as part of the broader realignment. Makary had previously aimed to expedite FDA approvals for drugs, devices, and vaccines, but his methods sparked controversy. Critics argued that his management of the drug approval process was too rigid, while others questioned his handling of tobacco regulations. The recent reversal on flavored e-cigarettes—something he initially resisted—further fueled speculation about his effectiveness.

Key Moments Leading to the Resignation

Makary’s resignation coincided with his planned testimony before the Senate Appropriations Committee regarding the FDA’s budget. The timing of his departure added to the political weight of the decision, as it came just days before he was set to address legislative concerns. Politico was the first to report the news, highlighting the sudden nature of the announcement.

The push for Makary’s removal gained momentum in recent days, driven by a group of White House and HHS officials who viewed the FDA as a source of dysfunction. They cited internal disputes, policy confusion, and a lack of clear direction as reasons for his departure. While Makary had attempted to reassure Trump of his support, the administration’s final decision to oust him caught him off guard. Sources suggest that the rejection of fruit-flavored e-cigarettes was the catalyst for the move, with Trump expressing frustration over the issue.

After weeks of debate, the FDA reversed its position on flavored e-cigarettes, indicating a shift in strategy. This reversal was seen as a concession to pressure from key allies within the administration and industry. However, it also underscored the challenges Makary faced in maintaining his stance. The episode has raised questions about the balance between regulatory rigor and political influence within the FDA.

Legacy and Future of the FDA

Makary, a physician and author, had initially pledged to streamline the FDA’s decision-making process. His focus on expediting approvals was part of a broader effort to modernize the agency. Yet, over the past year, he has encountered resistance from pharmaceutical companies and internal factions. The constant turnover in senior roles and conflicting priorities have complicated his agenda, leading to a lack of cohesive leadership.

While his exit closes one leadership gap, it opens new questions about the FDA’s direction under Trump’s new appointee. The agency will now need to navigate the complexities of health policy, balancing industry interests with public health goals. Makary’s departure also highlights the impact of political dynamics on regulatory decisions, as seen in the e-cigarette controversy. His resignation serves as a reminder of the challenges faced by senior officials in maintaining independence in a politicized environment.

With the FDA’s leadership in flux, the administration aims to consolidate control and ensure alignment with its health policies. The new acting chief, Diamantas, is expected to focus on stabilizing operations and addressing the concerns that led to Makary’s removal. As the search for a permanent commissioner continues, the Senate will play a critical role in shaping the agency’s future. This development underscores the ongoing efforts to restructure key departments and strengthen the administration’s health agenda amid shifting priorities and political pressures.